Asthma Drugs Get New Rules After FDA Finds Death Link
The U.S. Food and Drug Administration has moved to restrict the use of long-acting beta agonists, asthma drugs marketed by AstraZeneca PLC, Novartis AG and GlaxoSmithKline PLC that FDA analyses have...To view the full article, register now.
Already a subscriber? Click here to view full article